These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1339106)

  • 1. Chemotherapy in small cell lung cancer--from view point of dose intensity.
    Nakai Y; Koinumaru S; Suzuki S; Saito J; Sugawara S; Numata Y; Sato J; Matsubara N; Motomiya M
    Tohoku J Exp Med; 1992 Oct; 168(2):427-30. PubMed ID: 1339106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
    Murray N; Livingston RB; Shepherd FA; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin JW; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
    J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Small cell lung cancer: a retrospective analysis of results of chemotherapy and combined modality treatment].
    Ohnoshi T; Hiraki S; Ueoka H; Kawahara S; Numata T; Nishii K; Yonei T; Yamashta H; Kiura K; Kozuka A
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1341-8. PubMed ID: 2543304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy dose intensity in small cell lung cancer.
    Souhami RL; De Elvira MC
    Lung Cancer; 1994 Mar; 10 Suppl 1():S175-85. PubMed ID: 8087508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial.
    Oh IJ; Kim KS; Park CK; Kim YC; Lee KH; Jeong JH; Kim SY; Lee JE; Shin KC; Jang TW; Lee HK; Lee KY; Lee SY
    BMC Cancer; 2016 Aug; 16(1):690. PubMed ID: 27566413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.
    Ardizzoni A; Tjan-Heijnen VC; Postmus PE; Buchholz E; Biesma B; Karnicka-Mlodkowska H; Dziadziuszko R; Burghouts J; Van Meerbeeck JP; Gans S; Legrand C; Debruyne C; Giaccone G; Manegold C;
    J Clin Oncol; 2002 Oct; 20(19):3947-55. PubMed ID: 12351591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer.
    Murray N; Shah A; Osoba D; Page R; Karsai H; Grafton C; Goddard K; Fairey R; Voss N
    J Clin Oncol; 1991 Sep; 9(9):1632-8. PubMed ID: 1651995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
    J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: a Southwest Oncology Group pilot study.
    Taylor CW; Crowley J; Williamson SK; Miller TP; Taylor SA; Giri TG; Stephens RL; Livingston RB
    J Clin Oncol; 1990 Nov; 8(11):1811-7. PubMed ID: 2172473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dose-response effect of drugs in the chemotherapy of small-cell bronchial carcinoma].
    Kostić D; Jelić S; Radulović S
    Srp Arh Celok Lek; 2000; 128(3-4):75-9. PubMed ID: 10932613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
    Lorigan P; Woll PJ; O'Brien ME; Ashcroft LF; Sampson MR; Thatcher N
    J Natl Cancer Inst; 2005 May; 97(9):666-74. PubMed ID: 15870437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Randomized comparative study of CE (CDDP plus etoposide) and CE-AVN (ACNU, VCR plus procarbazine) as combined anticancer chemotherapy in small cell cancer of the lung].
    Kinoshita S; Bandou H; Yamashita T; Fukuta K; Yamasaki K; Matsuura A; Shimizu E; Ogura T; Doi H; Nakamura T
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 1):643-8. PubMed ID: 2833178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party.
    Sculier JP; Paesmans M; Bureau G; Dabouis G; Libert P; Vandermoten G; Van Cutsem O; Berchier MC; Ries F; Michel J
    J Clin Oncol; 1993 Oct; 11(10):1858-65. PubMed ID: 8410110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.
    Miles DW; Fogarty O; Ash CM; Rudd RM; Trask CW; Spiro SG; Gregory WM; Ledermann JA; Souhami RL; Harper PG
    J Clin Oncol; 1994 Jan; 12(1):77-82. PubMed ID: 7505809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.
    Pujol JL; Daurès JP; Rivière A; Quoix E; Westeel V; Quantin X; Breton JL; Lemarié E; Poudenx M; Milleron B; Moro D; Debieuvre D; Le Chevalier T
    J Natl Cancer Inst; 2001 Feb; 93(4):300-8. PubMed ID: 11181777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC; Mulshine JL; Kramer BS; Steinberg SM; Linnoila RI; Gazdar AF; Edison M; Phelps RM; Lesar M; Phares JC
    J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-cell lung cancer, high growth rate, high response rate to chemotherapy: ideal for high-dose chemotherapy?
    Galani E; Ellis PA; Harper PG
    J Clin Oncol; 2002 Oct; 20(19):3941-3. PubMed ID: 12351589
    [No Abstract]   [Full Text] [Related]  

  • 18. Influence of age on the treatment of limited-stage small-cell lung cancer.
    Siu LL; Shepherd FA; Murray N; Feld R; Pater J; Zee B
    J Clin Oncol; 1996 Mar; 14(3):821-8. PubMed ID: 8622030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
    Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
    Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination versus alternating chemotherapy in small-cell lung cancer.
    Lai SL; Perng RP
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jul; 63(7):513-20. PubMed ID: 10934803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.